ELI LILLY & Co is 105.7x more valuable than Summit Therapeutics Inc. by market capitalization ($1.070 T vs $10.13 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SMMT | LLY |
|---|---|---|
| Market cap | $10.13 B | $1.070 T |
| US-listed rank | #935 | #10 |
| Revenue (latest FY) | $0.00 | $65.18B |
| Net income (latest FY) | -$1.08B | $20.64B |
| Net margin | - | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 532 | 989 |
ELI LILLY & Co is 105.7x more valuable than Summit Therapeutics Inc. by market capitalization ($1.070 T vs $10.13 B).
In their latest fiscal years, Summit Therapeutics Inc. reported $0.00 in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Summit Therapeutics Inc. and ELI LILLY & Co, or browse the full rankings.